Cell reports. Medicine · 2026
Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Le Bac Viet, Vekariya Umeshkumar, Toma Monika M, Nieborowska-Skorska Margaret, Caron Marie-Christine, Gozdecka Malgorzata, Haydar Zayd, Walsh Martin, Ghosh Jayashri, Vaughan-Williams Elaine, Podszywalow-Bartnicka Paulina, Kukuyan Anna-Mariya, Ziolkowska Sylwia, Atkins Jessica, Hadzijusufovic Emir, Chandramouly Gurushankar, Nejati Reza, Piwocka Katarzyna, Pomerantz Richard, Vassiliou George S, Huntly Brian J P, Valent Peter, Wasik Mariusz, Bellacosa Alfonso, Masson Jean-Yves, Gupta Gaorav P, Challen Grant A, Skorski Tomasz
Аннотация
Myeloid malignancies carrying somatic DNMT3A mutations (DNMT3Amut) are refractory to standard therapy. DNMT3Amut leukemia cells accumulate toxic DNA double-strand breaks (DSBs) and stalled replication forks, rendering them dependent on DNA damage response (DDR). We report here that DNA polymerase theta (Polθ), a key element in DSB repair by end-joining (Polθ-mediated end-joining [TMEJ]) and in fork restarting, promotes survival and proliferation of DNMT3Amut leukemia cells. Polθ is overexpressed in DNMT3Amut leukemia cells due to abrogation of PARP1 PARylation-dependent UBE2O E3 ligase-mediated ubiquitination and proteasomal degradation of Polθ. In addition, PARP1-mediated recruitment of the SMARCAD1-MSH2/MSH3 repressive complex to DSBs is diminished in DNMT3Amut leukemia cells, which facilitates association of Polθ with DNA damage. Polθ inhibitors enhance the anti-leukemic effects of standard drugs such as FLT3 kinase inhibitor quizartinib, cytarabine ± doxorubicin, and etoposide in vitro and in mice with DNMT3Amut leukemia. Altogether, Polθ is an attractive target in DNMT3Amut hematological malignancies.